What happened with DNLI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Denali Therapeutics develops treatments for diseases including Alzheimer’s, Parkinson’s and Hunter syndrome. Its TransportVehicle platform is designed to carry medicines across the blood-brain barrier, which limits their access to the brain. Its lead candidate, tividenofusp alfa, is being developed for Hunter syndrome. As of its latest filing, Denali had no approved drugs or product-sales revenue; it had built U.S. commercial infrastructure for a potential launch, subject to approval.
Drugmakers pay Denali to obtain rights to its programs and help develop them. All revenue to date has come from collaboration and license agreements, through payments such as upfront fees and development milestones. Denali also funds operations through stock sales. Biogen is co-developing the Parkinson’s candidate BIIB122/DNL151, while Sanofi funds and develops the licensed ulcerative-colitis candidate eclitasertib. Takeda is another development and funding partner.
These agreements give Denali potential milestone payments and, if partnered drugs reach the market, royalties or shared profits. That income depends on partners advancing the programs and obtaining approvals. Denali retains worldwide rights to tividenofusp alfa, but cannot begin product sales without regulatory approval; future sales also depend partly on insurers and government health programs covering treatment.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Denali’s prospects hinge on getting its brain-penetrant therapies approved and sold, with two rivals absent from this list worth watching: JCR Pharmaceuticals in Hunter syndrome and Roche/Genentech in brain-delivery platforms.
Biogen shares Denali’s development costs and potential profits on the Parkinson’s drug BIIB122, while their Alzheimer’s treatments compete. Biogen’s LUMA trial in early-stage Parkinson’s disease directly tests their shared asset; Biogen funds 60% of agreed global development costs and leads global commercialization.
REGENXBIO’s RGX-121 gene therapy competes with Denali’s tividenofusp alfa for Hunter syndrome patients, including treatment of neurological manifestations. Progress on RGX-121, developed and planned for commercialization with Nippon Shinyaku, is the competitive news to watch for Denali’s lead drug.
Sanofi funds development of peripheral RIPK1 drugs licensed from Denali and may pay it milestones and a share of sales as royalties, while Sanofi’s marketed Elaprase competes with Denali’s lead Hunter syndrome therapy. Its Phase 2 ulcerative colitis study of eclitasertib is a concrete test of the licensed program’s progress.
Takeda’s marketed Elaprase competes with Denali’s Hunter syndrome treatment, and Takeda reported notifying Denali in April 2026 that it was ending their entire development collaboration. That termination includes co-development of DNL593/TAK-594, rather than leaving the progranulin program as a continuing partnership.
Alector challenges Denali across brain-penetrant antibodies, gene-silencing medicines and progranulin treatments for overlapping neurodegenerative diseases. Its GSK-backed Phase 2 trial of the progranulin-elevating antibody nivisnebart in early Alzheimer’s disease is the clinical program to watch, alongside its preclinical brain-penetrant anti-amyloid and tau-silencing programs.
Ultragenyx’s MPS IIIA development program competes with Denali’s DNL126 enzyme-replacement treatment for the same rare-disease patients. With no approved drug treatments for MPS IIIA in the supplied filing, progress toward an effective treatment is the competitive development to follow.
Ionis’s RNA-targeted neurological drugs compete with Denali’s Alzheimer’s and Parkinson’s programs, including Denali’s approach to delivering gene-silencing medicines into the brain. Ionis’s advances in potency and durability provide a comparison for Denali’s tau-targeting DNL628, whose initial clinical biomarker data are targeted for the first half of 2027.
Prothena’s Parkinson’s and Alzheimer’s therapies compete with Denali’s efforts to change the course of those diseases. Watch prasinezumab, which Prothena licensed to Roche in return for milestone payments and potential sales royalties, and its Alzheimer’s programs for evidence of competing treatment progress.
Passage Bio’s PBFT02 gene therapy competes with Denali’s recombinant progranulin treatment for frontotemporal dementia caused by GRN mutations. Its work on a more efficient PBFT02 manufacturing process and a potency test for late-stage trials shows how it is preparing that competing treatment for further development.
Voyager competes with Denali in getting treatments across the blood-brain barrier and developing Alzheimer’s and Parkinson’s therapies, with partners paying Voyager license fees, milestones and research reimbursements. Its TRACER platform uses viral shells to deliver gene therapies intravenously, offering a different route from Denali’s antibody and oligonucleotide carriers.
Dyne competes with Denali on delivery platforms that use the transferrin receptor to carry treatments into tissues, including brain-penetrant enzyme replacement for Pompe disease. Dyne’s FORCE-GAA cleared glycogen in muscle and the central nervous system in mice, so further progress would test a competing approach to Denali’s Pompe program.
Acumen’s sabirnetug competes with Denali’s DNL921 as an anti-amyloid antibody intended to change the course of Alzheimer’s disease. Sabirnetug’s safety, efficacy and method of administration are the concrete comparisons to watch as Denali tests whether DNL921’s brain-delivery design translates into clinical benefit.
Lilly already markets the Alzheimer’s drug Kisunla and also develops blood-brain-barrier delivery technologies and neurodegenerative treatments that compete with Denali’s pipeline. Kisunla’s clinical and commercial progress provides a comparison for Denali’s DNL921 on efficacy, safety and the value offered to patients and payers.
Biogen Inc. earningsBIIB
Biogen’s report will show how its LUMA trial is progressing for BIIB122, the Parkinson’s drug it is developing with Denali.
Look for clinical progress in LUMA and whether Biogen continues to advance the study. Progress and continued investment would support the case for advancing this shared asset; a setback or slowdown would make the program’s prospects—and Denali’s share of its development costs—less certain.
Sanofi earningsSNY
Sanofi’s report will show whether its phase 2 eclitasertib study in ulcerative colitis is advancing the peripheral RIPK1 program licensed from Denali.
Look for whether Sanofi reports progress in the phase 2 study. Advancement would make potential milestone payments and royalties to Denali more tangible; a pause or setback would leave those possible payments less certain.
Ultragenyx Pharmaceutical Inc. earningsRARE
Ultragenyx’s report will show whether its MPS IIIA program is advancing against Denali’s DNL126 for the same rare-disease patients.
Look for clinical advancement in Ultragenyx’s MPS IIIA program. Progress would point to another possible treatment for these patients and a clearer competitor for Denali’s DNL126; no progress would leave that competing path less certain.
Ionis Pharmaceuticals, Inc. earningsIONS
Ionis’s report will show whether its RNA-targeted neurological drugs are advancing, a comparison point for Denali’s brain-delivery and tau-targeting programs.
Look for reported gains in the potency or durability of Ionis’s neurological drugs. Such gains would raise the comparison bar for Denali’s effort to deliver gene-silencing medicines into the brain; limited progress would leave less evidence of a competing advantage.
Denali Therapeutics Inc. earningsThis company
Denali Therapeutics’ report will show whether collaboration revenue and cash on hand are keeping pace with the cost of advancing its drug candidates toward commercialization.
Read collaboration revenue alongside cash used in operations. More collaboration revenue with slower cash use would show that partner payments are helping support development and commercialization spending. Less collaboration revenue with faster cash use would show Denali relying more on its cash reserves to fund that work, making future funding needs more pressing.
REGENXBIO Inc. earningsRGNX
REGENXBIO’s report will show whether its Hunter syndrome gene therapy RGX-121 is advancing as a competing option to Denali’s lead candidate.
Look for whether RGX-121 advances and whether REGENXBIO reports progress relevant to neurological manifestations. Advancement would make another potential treatment path more credible for Hunter syndrome patients and add competition for Denali’s lead candidate; a setback would weaken that competitive evidence.
